Congenital Abnormalities  >>  eleclazine (GS-6615)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
eleclazine (GS-6615) / Gilead
NCT02300558 / 2014-000042-30: Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Terminated
3
41
US, Canada, Europe, RoW
Eleclazine, GS-6615, Eleclazine placebo
Gilead Sciences
Long QT Syndrome Type 3
12/16
02/17

Download Options